Drugs / CD19/BCMA CAR T-cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07266337 | Dec 2025 → Dec 2035 expected | systemic lupus erythematosus | Chengdu Ucello Biotechnology Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD19/BCMA CAR-T cells | “intravenous injection of CD19/BCMA CAR-T cells” NCT07266337 ↗ |
| Modality | Cell therapy | “CD19/BCMA CAR-T cell product” NCT07266337 ↗ |
| Route | Intravenous | “intravenous injection of CD19/BCMA CAR-T cells” NCT07266337 ↗ |
| Target | CD19 | “CD19/BCMA CAR-T cells” NCT07266337 ↗ |